We have expressed human pre-procorticotrophin\x=req-\ releasing hormone (pre-proCRH) as a fusion protein to \g=b\-galactosidase in Escherichia coli. The chimeric fusion protein was found in insoluble bacterial inclusion bodies. The inclusion bodies were isolated, purified and solubilized, and used as imunogens in rabbits to raise antibodies against the neuropeptide moiety. The antibodies generated were characterized by immunoassays and immunocytochemical techniques. The immunoassay results showed that the recombinant pre-proCRH antibodies cross\x=req-\ reacted with the full-length CRH precursor and several cleavage products derived from it, i.e. CRH(1\p=n-\41) and CRH(36\p=n-\41). They did not cross\x=req-\ react with the CRH antagonist CRH(9\p=n-\41). Extracts of stalk median eminence from various species were also studied. The antibodies cross-reacted with extracts from ovine, bovine, human and rat tissues, exhibiting parallel displacement curves to that of synthetic rat/human CRH(1\p=n-\41) used as standard. They also cross-reacted with a skin extract of the frog, a species known to contain a CRH-related peptide, i.e. sauvagine, in this tissue. The immunocytochemical studies demonstrated that the antibodies generated against recombinant human preproCRH labelled neurones in the rat paraventricular nucleus of the hypothalamus. They exhibited the same pattern of staining as that obtained with an antibody generated against synthetic CRH(1\p=n-\41).
INTRODUCTION
Antibodies against prohormones and their products of post-translational processing are useful tools to study their complex biosynthetic pathways and the biological activity of the processed products. Small peptides, although invariably antigenic, are not always immunogenic and therefore require attach¬ ment to a carrier molecule to induce an immune response in recipient animals (Arnon, Maron, Sela & Anfinsen, 1971) . These conjugates are not well defined with respect to their coupling sites and the ratio of peptide to carrier, and considerable hetero¬ geneity may therefore arise in a population of coupled molecules.
An alternative method to obtain specific anti¬ bodies is to construct a fusion protein between the gene encoding for a bacterial protein and the gene of interest (e.g. human pre-procorticotrophin-releasing hormone (pre-proCRH)), express the fusion protein in Escherichia colt and purify sufficient amounts of it to be used as immunogen (Carroll & Scott, 1985; Lowenadler, Nilsson, Abrahamsen et al. 1986 ; Spruce, Jackson, Lowry et al. 1988 ). The purifica¬ tion of fusion proteins is usually hampered by their insolubility in the bacterial host (Shine, Fettes, Lan et al. 1980; Paul, Van Frank, Muth et al. 1983) . In this paper we describe the use of isolated, solubilized inclusion bodies from E. coli expressing the recom¬ binant ß-galactosidase-pre-proCRH fusion protein, as immunogen to raise specific antibodies against the neuropeptide precursor moiety. This approach has several advantages. It provides an unlimited source of immunogen and eliminates the need for handling human or animal tissues, hence preventing exposure to putative pathogens. Furthermore, although prohormones are usually highly unstable, when ex¬ pressed as fusion proteins within a bacterial milieu they appear to be protected from degradation. Finally, owing to their conjugation to a highly immunogenic bacterial protein, they are in the form of a ready-made 'hapten-carrier' complex.
Utilizing this approach, we have raised polyclonal antibodies which recognize the naturally occurring CRH precursor together with some of its products of post-translational processing. We describe their cross-reactivities, using biochemical and immunocytochemical assays, and present data showing that our antibodies cross-react with immunoreactive CRH and other related peptides found in various vertebrate species.
MATERIALS AND METHODS

Bacterial strains and plasmids
The bacterial host used was the TG2 strain of E. coli which is lac Z~, but carries the mutation lac iq on the F' plasmid. The plasmid pUR 292 (Rüther & Muller-Hill, 1983) (Maniatis, Fritsch & Sambrook, 1982) . ) construct has been described in detail elsewhere (Castro et al. 1990 ). , were cultured over¬ night in 100 ml L-broth (1% (w/v) Bacto-tryptone, 0-5% (w/v) Bacto-yeast extract and 1% (w/v) NaCl (pH 7É5); bacteriological powders were obtained from Lab M Ltd, Salford, Greater Manchester, U.K. containing 100 ug ampicillin/ml and 500 um isopropyl-ß-D-thiogalactopyranoside (IPTG; Sigma Chemical Co., Poole, Dorset, U.K.). Cells were then harvested at 6000 £ at 4°C for 10 min in a Sorvall GSA rotor. The isolation of inclusion bodies has been described previously (Marston, 1985; Castro et al. 1990 ).
Sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) electroelution E. coli TG2 cells transformed with phPPC were cultured overnight in 100 ml L-broth contain¬ ing 100 ug ampicillin/ml and 500 (im IPTG. Cells were harvested at 6000 ¿* at 4°C for 10 min. The bacterial pellet was washed with ice-cold phosphatebuffered saline (PBS), recentrifuged as described above, then resuspended in 20 ml SDS-PAGE sample buffer plus 1 mM phenymethylsulphonyl fluoride and 2 ug leupeptin/ml. The sample was subjected to several short bursts of sonication at 0°C and then placed in a boiling water bath for 5 min. Aliquots of the lysate were stored at -20°C awaiting SDS-PAGE followed by electroelution. This procedure has been described in detail else¬ where (Castro et al. 1990 ). Immunoblot analysis Proteins were separated on polyacrylamide gels, then electrophoretically transferred to nitrocellulose sheets in a Bio-Rad Transblot apparatus according to the method of Towbin, Staetelin & Gordon (1979) . Western blotting was performed as de¬ scribed previously (Castro et al. 1990 ). One of the primary antibodies used (Dom2) was raised in rabbits, in our laboratory, against synthetic human proCRH (125-151) (Peninsula Laboratories, St Helens, Merseyside, U.K.) coupled to porcine thyroglobulin. The other primary antibody used, 3B3 (code: rCRF3B3), was also raised in rabbits, in our laboratory, against synthetic rat/human (r/h) CRH(1-41) (Peninsula Laboratories) coupled to porcine thyroglobulin (Linton & Lowry, 1986 39-6% (v/v) propylene glycol (BDH)), and 150 ug colchicine (BDH) dissolved in 10 ul sterile 0-9% (w/v) NaCl were injected into the lateral ventricle with a stereotaxic device. The animals were killed, 48 h later, with an overdose of the anaesthetic, and perfused through a cannula inserted into the left ventricle of the heart. Oxygenated Tyrode solution (NaCl, 137 mM; KC1, 2-7 mM; CaCl2, 1-8 mM; Na2HP04, 0-3 mM; glucose, 5-56 mM; NaHC03, 11-6 mM; gassed with 97% (v/v) 02/3% (v/v) C02 (pH 7-2)) was perfused for 2 min, followed by 300 ml 4% (w/v) (Sternberger, 1979 showed the appearance of a new band of 140 kDa, i.e. the size expected for the ß-galactosidase-pre-proCRH fusion protein (Fig. la, lane 1) Preparative SDS-PAGE followed by electroelu¬ tion was used as an alternative procedure to purify the fusion protein (Castro et al. 1990 ). Figure 1, To characterize further the antibodies generated, we performed cross-reactivity studies using several CRH-derived synthetic fragments to displace the binding of 125I-labelled r/hCRH(l-41) (Fig. 2) .
The antibodies were used at a final dilution of 1:3000, which gave a total binding of 30-50%; all antisera had a sensitivity of 20 pg/tube. The anti¬ bodies showed no cross-reactivity (100 pg-500 ug/ tube) with adrenocorticotrophin (ACTH), arginine vasopressin, sauvagine and with the CRH antag¬ onist, CRH(9-41). Urotensin I only exhibited slight cross-reactivity at doses above 250 ug/ml with all the antibodies (results not shown). Ovine CRH(1-41) showed a displacement curve parallel to that of r/hCRH(l-41) for antibodies MP2 and MP3 ( Fig. 2a and b) . Antibodies MP4 and MP6 (Fig. 2d and c) also exhibited cross-reactivity with ovine CRH(1-41). All the antibodies cross-reacted with r/hCRH(36-41) except antibody MP4 which exhib¬ ited slight cross-reactivity at doses above 50 ng peptide/ml. Only antibodies MP2 and MP6 crossreacted with r/hCRH(l-20) (see Fig. 2a and c) . Cross-reactivity of ß-galactosidase-preproCRH fusion protein antibodies with extracts from phylogenetically diverse SME In order to evaluate the specificity of the antibodies generated, SME extracts from several species, assayed at several dilutions, were tested for their ability to inhibit the binding of 125I-labelled r/hCRH(l-41) to the antisera. As can be seen in Fig. 3, (Rivier, Rivier & Vale, 1984) . This could explain the cross-reactivity and parallelism observed among the displacement curves of the different SME extracts from the mammalian species analysed using the antibodies raised against human preproCRH fusion protein. Frog skin extract exhibited a weaker cross-reactivity with all the antibodies tested, and the displacement curve was not strictly parallel to that of r/hCRH(l-41). This is not surprising, since the frog skin CRH-related peptide, i.e. sauvagine, shares approximately only 50% homology with r/hCRH(l-41) (Rivier et al. 1984) .
Immunocytochemical studies of rat hypothalamus All three antisera used (i.e. 3B3, MP4 and MP6) stained neurones in the paraventricular nucleus of the hypothalamus, as well as in the supraoptic nucleus (Fig. 4) (Fig. 4b and c ) was analogous to those previously reported with antisera generated against synthetic CRH(1-41) (Makara, Antoni, Stark & Karteszi, 1984; Antoni, 1986; Sawchenko, 1987) and to our results with the 3B3 antibody (see Fig. 4a ). (Taniguchi, Guarents, Roberts et al. 1980; Davies, Bos, Veda et al. 1983) (Shine et al. 1980; Shen, 1984; Castro et al. 1990 ).
ß-Galactosidase-pre-proCRH fusion protein to be used as antigen was partially purified by washing the insoluble material after cell lysis followed by treatment with 8 M urea to achieve solubilization of the inclusion-like bodies. Preparative SDS-PAGE followed by electroelution was used as an alternative procedure to purify the fusion protein. Purified fusion protein prepared by each of these methods was used as antigen to raise specific antibodies in rabbits. All of the rabbits produced fusion protein antibodies after the second booster injection. The antibodies generated were further characterized using RIAs and immunocytochemistry. Although two different approaches were used to prepare immunogemsolubilization of inclusion bodies and preparative SDS-PAGE followed by electroelution, the differences in the immune responses observed in the rabbits utilized for this study appear to be due to different individual immune responses rather than to differences which could be ascribed to the antigen used. All the antibodies generated recognized r/hCRH(l-41), yielding similar sensitivities. MP2 and MP3 antibodies showed complete displacement with ovine CRH(1-41), while MP4 and MP6 exhibited partial displacement. None of the anti¬ bodies recognized the CRH antagonist, i.e. oc-helical CRH(9-41). This could be due to the several amino acid substitutions which occur within the primary sequence of this peptide or to its different tertiary structure (Rivier et al. 1984) . The latter could also explain why antibodies MP3 and MP6 reacted almost completely with r/hCRH(36-41) but not at all with CRH(9-41), although it contains the same figure 4. Immunostaining of coronal sections of the para¬ ventricular nucleus of rat hypothalamus with antisera: 3B3 rat/human corticotrophin-releasing hormone(l-41) (r/hCRH(l-41)), Alternatively, the antibodies towards the ß-galac¬ tosidase moeity can also be absorbed on a ß-galactosidase affinity column.
Our immunocytochemical studies demonstrate that antibodies generated against recombinant human pre-proCRH label neurones in the rat para¬ ventricular nucleus. Previous immunocytochemical studies performed using antibodies generated against ovine or r/hCRH(l-41) showed a similar staining distribution of CRH-immunoreactive cells in the rat hypothalamic paraventricular nucleus (Swanson, Sawchenko, Rivier & Vale, 1983; Sakanaka, Shibasaki & Lederis, 1987 
